Monday, 07 March 2022 09:00 AM
Company Update
SAN MARCOS, CA / ACCESSWIRE / March 7, 2022 / ArtVentive Medical Group, a leading provider of therapeutic embolization products, today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its new EOS-X Endoluminal Occlusion System.
"We are excited to receive this pre-marketing clearance for EOS-X, which represents a significant milestone for our company and major advancement for millions of patients." said Bill Olson, Chief Executive Officer at ArtVentive. "EOS-X brings almost double the size range, lower crossing profile, and enhanced retrievability to the proven EOS family platform, and of course continues to deliver the instant, precise, and permanent occlusion that EOS is known for around the world."
ArtVentive President & CTO Leon Rudakov commented, "ArtVentive was founded out of clinical need for better embolization technology, and with a plan to build a platform of devices for embolization, interventional oncology, structural heart disease, and more. Over the past several years, EOS has been used in patients globally with excellent results. EOS-X represents a leap forward in capabilities and economic value, and builds on the foundation of our previous clinical experience."
Millions of patients globally suffer from vascular disease or malformations that require embolization procedures. The ArtVentive Endoluminal Occlusion System - EOS-X is indicated for arterial and venous embolization in the peripheral vasculature. EOS-X delivers immediate, precise, and permanent occlusion in vessels from 2-16mm in diameter.
About ArtVentive Medical Group, Inc.
ArtVentive Medical has developed the EOS embolization plug family, which is approved for use around the world for therapeutic embolization in the peripheral vasculature. EOS offers immediate, precise and permanent occlusion and has successfully been used in thousands of patients to-date.
Contact:
ArtVentive Medical
San Marcos, CA
www.artventivemedical.com
[email protected]
SOURCE: ArtVentive Medical